DeHeng Assisted Haixi Pharma in Listing on HKEX

2025-10-20

On October 20, 2025, Fujian Haixi Pharmaceuticals Co., Ltd. (“Haixi Pharma”, Stock Code: 2637.HK) officially commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited. Haixi Pharma offered its shares at HKD 86.40 per share, raising total gross proceeds of approximately HKD 994 million.

As the issuer’s PRC legal counsel for this offering and listing, the DeHeng team was led by partner Long Wenjie from its Shanghai Office, with primary support from lawyer Ma Haoran from the Shanghai Office, lawyer Su Zhongzheng from the Wenzhou Office, and lawyer Yan Mingkang from the Shanghai Office. The team worked closely with the issuer and various cooperating institutions and provided comprehensive, professional, high-quality, and efficient end-to-end legal services for this project.